• Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Daniel I Swerdlow, Michael V Holmes, Karoline B Kuchenbaecker, Jorgen E L Engmann, Tina Shah, Reecha Sofat, Yiran Guo, Christin... more a Chung, Anne Peasey, Roman Pfister, Simon P Mooijaart, Helen A Ireland, Maarten Leusink, Claudia Langenberg, Ka Wah Li, Jutta Palmen, Philip Howard, Jackie A Cooper, Fotios Drenos, John Hardy, Michael A Nalls, Yun Rose Li, Gordon Lowe, Marlene Stewart, Suzette J Bielinski, Julian Peto, Nicholas J Timpson, John Gallacher, Malcolm Dunlop, Richard Houlston, Ian Tomlinson, Ioanna Tzoulaki, Jian'an Luan, Jolanda M A Boer, Nita G Forouhi, N Charlotte Onland-Moret, Yvonne T van der Schouw, Renate B Schnabel, Jaroslav A Hubacek, Ruzena Kubinova, Migle Baceviciene, Abdonas Tamosiunas, Andrzej Pajak, Roman Topor-Madry, Sofia Malyutina, Damiano Baldassarre, Bengt Sennblad, Elena Tremoli, Ulf de Faire, Luigi Ferrucci, Stefania Bandenelli, Toshiko Tanaka, James F Meschia, Andrew Singleton, Gerjan Navis, Irene Mateo Leach, Stephan J L Bakker, Ron T Gansevoort, Ian Ford, Stephen E Epstein, Mary Susan Burnett, Joe M Devaney, J Wouter Jukema, Rudi G J Westendorp, Jan de BorstGertG, Yolanda van der Graaf, Pim A de Jong, Anke-Hilse Mailand-van der Zee, Olaf H Klungel, Anthonius de Boer, Pieter A Doevendans, Jeffrey W Stephens, Charles B Eaton, Jennifer G Robinson, JoAnn E Manson, F Gerry Fowkes, Timonthy M Frayling, Jackie F Price, Peter H Whincup, Richard W Morris, Debbie A Lawlor, George Davey Smith, Yoav Ben-Shlomo, Susan Redline, Leslie A Lange, Meena Kumari, Nick J Wareham, VerschurenW M MoniqueWM, Emelia J Benjamin, John C Whittaker, Anders Hamsten, Frank Dudbridge, J A Chris Delaney, Andrew Wong, Diana Kuh, Rebecca Hardy, Berta Almoguera Castillo, John J Connolly, Pim van der Harst, Eric J Brunner, Michael G Marmot, Christina L Wassel, Steve E Humphries, Philippa J Talmud, Mika Kivimaki, Folkert W Asselbergs, Mikhail Voevoda, Martin Bobak, Hynek Pikhart, James G Wilson, Hakon Hakonarson, Alex P Reiner, Brendan J Keating, Naveed Sattar, Aroon D Hingorani, and Juan Pablo Casas. less
• Lancet. 2012 Mar 31; 379 (9822): 121412241214-24.

BackgroundA high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.MethodsApplying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the gene IL6R to evaluate the likely efficacy and safety of IL6R inhibition for primary prevention of coronary heart disease. We compared genetic findings with the effects of tocilizumab reported in randomised trials in patients with rheumatoid arthritis.FindingsIn 40 studies including up to 133,449 individuals, an IL6R SNP (rs7529229) marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala) was associated with increased circulating log interleukin-6 concentration (increase per allele 9·45%, 95% CI 8·34-10·57) as well as reduced C-reactive protein (decrease per allele 8·35%, 95% CI 7·31-9·38) and fibrinogen concentrations (decrease per allele 0·85%, 95% CI 0·60-1·10). This pattern of effects was consistent with IL6R blockade from infusions of tocilizumab (4-8 mg/kg every 4 weeks) in patients with rheumatoid arthritis studied in randomised trials. In 25,458 coronary heart disease cases and 100,740 controls, the IL6R rs7529229 SNP was associated with a decreased odds of coronary heart disease events (per allele odds ratio 0·95, 95% CI 0·93-0·97, p=1·53×10(-5)).InterpretationOn the basis of genetic evidence in human beings, IL6R signalling seems to have a causal role in development of coronary heart disease. IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials. Genetic studies in populations could be used more widely to help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses.FundingUK Medical Research Council; British Heart Foundation; Rosetrees Trust; US National Heart, Lung, and Blood Institute; Du Pont Pharma; Chest, Heart and Stroke Scotland; Wellcome Trust; Coronary Thrombosis Trust; Northwick Park Institute for Medical Research; UCLH/UCL Comprehensive Medical Research Centre; US National Institute on Aging; Academy of Finland; Netherlands Organisation for Health Research and Development; SANCO; Dutch Ministry of Public Health, Welfare and Sports; World Cancer Research Fund; Agentschap NL; European Commission; Swedish Heart-Lung Foundation; Swedish Research Council; Strategic Cardiovascular Programme of the Karolinska Institutet; Stockholm County Council; US National Institute of Neurological Disorders and Stroke; MedStar Health Research Institute; GlaxoSmithKline; Dutch Kidney Foundation; US National Institutes of Health; Netherlands Interuniversity Cardiology Institute of the Netherlands; Diabetes UK; European Union Seventh Framework Programme; National Institute for Healthy Ageing; Cancer Research UK; MacArthur Foundation.Copyright © 2012 Elsevier Ltd. All rights reserved.

30 keywords...

hide…